Anavex Life Sciences Corp (AVXL)

[sokol]

Is AVXL 2-73 better or worse than the Alzheimer's drugs the FDA has approved up to now?

Previous to AVXL 2-73 clinical trials THIS WAS SAID:

''While there is no cure, prevention or treatment to slow the progression of Alzheimer's disease, there are five prescription medications approved by the U.S. Food and Drug Administration (FDA) to treat its symptoms.''...... (amyloid and such)

...Alzheimer's or dementia may change your sleep patterns. You may have difficulty sleeping, take daytime naps, and/or experience other shifts in your sleep pattern. Researchers are not sure why these sleep changes occur.

http://www.alz.org/i-have-alz/treatments-and-research.asp

In July of this year the AVXL 2-73 clinical trial results were updated SAYING THIS:

''In a disease state where progression is invariable over time, a sustained or stable MMSE and ADCS-ADL score is considered a positive outcome.''

“The demonstration of an extended period of both cognitive and functional stability out to 31 weeks in a patient population that would normally be expected to experience ongoing cognitive decline is an encouraging milestone in the development of ANAVEX 2-73. The 31-week data also validates the earlier observation of improvements on tasks within the Cogstate battery. The specificity and consistency of these benefits suggest that ANAVEX 2-73 can sustain activation of attentional and working memory functions with repeated dosing in Alzheimer’s disease,” said Associate Professor Stephen Macfarlane, FRANZCP, Head of Clinical Governance, Dementia Centre HammondCare, who is conducting the study. “Of noticeable interest was also HAM-D data showing beneficial effects of ANAVEX 2-73 on insomnia, agitation and anxiety at 31 weeks, which might suggest an additional important role of ANAVEX 2-73 for the amelioration of behavioral and psychological symptoms of dementia (BPSD).”''

http://www.anavex.com/?news=anavex-presents-31-week-efficacy-data-from-phase-2a-study-of-anavex-2-73-in-alzheimers-patients-at-aaic-2016

''...no statistically significant decline from baseline was reported, which is impressive.”

http://www.anavex.com/?news=anavex-confirms-data-from-phase-2a-study-of-anavex-2-73-in-alzheimers-patients-presented-at-aaic-2016

In a very recent interview Missling said this about AVXL 2-73 (from Xena's summary)

4) 2-73 is believed to address underlying cause and prevent progression

5) 2-73 works by restoring homeostasis of cells

6) Sigma 1 not utilized on a daily basis - is a safeguard.

7) 2-73 restores balance through s-1 receptor - Missling specifically states that there is a possibility to regain cognition

So, what may be expected from here? Do we expect AVXL 2-73 to be better than the 5 Alzheimer's drugs approved by the FDA up to now? Do we expect the December reported results to produce indications that AVXL 2-73 may be better than the 5 AZ drugs approved so far? I think so.